Selank ClinicalTrials.gov Registry: Trial Status and Research Access

Researchers searching ClinicalTrials.gov for Selank consistently come up empty — a fact that surprises many, since Selank has carried formal pharmaceutical registration in Russia since 2009 and has been the subject of published clinical research since the mid-2000s. This gap between international registry visibility and actual research history is the subject of this review.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.

Quick Answer: As of this review, ClinicalTrials.gov — the U.S. federal registry — lists no interventional trials under the name "Selank." The peptide's clinical evidence base instead comes from a trial registered through the Russian Ministry of Health approval pathway and subsequent peer-reviewed pharmacology studies, none of which carry a ClinicalTrials.gov NCT number.

TL;DR:

No NCT-numbered study currently lists Selank as a studied intervention on ClinicalTrials.gov.
Selank's core clinical evidence traces to a 2008 Russian trial (Zozulya et al., n=62) that supported its 2009 Russian Ministry of Health drug registration — a regulatory pathway separate from the FDA/ClinicalTrials.gov system.
Selank has no FDA approval and no publicly listed U.S. Investigational New Drug (IND) trial record.
Subsequent rodent pharmacology research (Kasian et al., 2017) has examined Selank's interaction with GABAergic signaling alongside diazepam.
Semax, Selank's frequently paired research peptide, shows the same registry pattern — extensive published research, no ClinicalTrials.gov listing.

What the registry search shows

A direct search of ClinicalTrials.gov for "Selank" returns zero matching interventional or observational study records. This stands in contrast to compounds like BPC-157, which has an actively recruiting Phase 2 trial (NCT07437547) tracked on the BPC-157 library profile, or MOTS-c, which now has a registered Phase 2a insulin-sensitivity trial. Selank and its research partner Semax do not have that kind of U.S. registry footprint.

That absence does not mean Selank is untested. Selank's clinical evidence originates from a different regulatory track entirely: Russian Ministry of Health drug registration, completed in 2009, built on a placebo- and comparator-controlled study published the year before. Zozulya and colleagues enrolled 62 patients with generalized anxiety disorder and neurasthenia, randomizing them to intranasal Selank (1,350 mcg/day) or the benzodiazepine medazepam for 14 days (PMID 18454096). Both arms showed comparable reductions on the Hamilton Anxiety Rating Scale, with the Selank group additionally showing antiasthenic effects not observed in the benzodiazepine comparator. That trial — and the registration it supported — never entered the ClinicalTrials.gov system because it was conducted and reviewed entirely within the Russian regulatory framework, which maintains its own trial registry separate from the U.S. system.

Selank and Semax: registry status compared

Researchers frequently study Selank alongside Semax, and the two compounds show an identical registry pattern:

Selank — No ClinicalTrials.gov listing. Primary evidence: the 2008 Russian GAD/neurasthenia trial (PMID 18454096) and later mechanistic rodent work, including a 2017 study on Selank's interaction with diazepam and GABAergic transmission (PMID 28280289).
Semax — No ClinicalTrials.gov listing. Semax has an even longer Russian regulatory history as an approved stroke-recovery and cognitive-support drug, with preclinical research continuing in transgenic Alzheimer's disease models examining amyloid pathology and cognitive performance.

The Selank and Semax comparison article covers how the two peptides' complementary anxiolytic and nootropic mechanisms are typically studied together in published protocols, even though neither has a U.S. trial registry entry to point to.

What this means for research access

For researchers evaluating Selank, the practical implication is straightforward: there is currently no FDA Investigational New Drug application or associated U.S. clinical trial to reference, and no ClinicalTrials.gov record to cite for regulatory-status purposes. The available evidence base sits entirely within Russian-language and Russian-registered literature, plus a smaller body of English-language mechanistic research published in international journals.

This matters for how Selank is currently treated in the U.S. regulatory conversation around compounded peptides. The FDA's ongoing Pharmacy Compounding Advisory Committee (PCAC) review process — covered in detail in the PCAC docket summary for Semax and related compounds — evaluates bulk drug substances based partly on the depth and quality of available safety and efficacy data, which typically means U.S. or ICH-region trial data. A compound with no ClinicalTrials.gov presence is, by definition, working from a thinner formal evidence base in that specific regulatory context, regardless of its registration status abroad.

Researchers tracking whether that changes — for Selank, Semax, or any other compound under active regulatory review — can monitor real-time trial registrations using the ClinicalTrials.gov trial tracker tool, which surfaces newly filed studies as they appear in the federal registry.

Timeline and what's next

There is no indication of a pending U.S. trial filing for Selank at this time. A new registration could emerge through several pathways: an investigator-initiated IND application from a U.S. academic center, a 505(b)(2) application referencing the existing Russian efficacy data as supporting literature, or a sponsor-initiated Phase 1 safety study designed to build a U.S.-specific data package. None of these appears to be in motion based on current registry data.

In the interim, researchers should treat Selank's Russian registration and the associated 2008 trial as the relevant clinical precedent, while recognizing that this evidence has not been evaluated by the FDA and does not carry the same regulatory weight as a ClinicalTrials.gov-registered study. Monitoring should continue alongside the broader July 2026 PCAC hearing cycle, where Russian-origin peptides are increasingly part of the discussion about international clinical data supporting bulk drug substance nominations.

External sources

PMID 18454096 — "[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]" (Zh Nevrol Psikhiatr Im S S Korsakova, 2008).
PMID 28280289 — "Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats" (Behavioural Neurology, 2017).
ClinicalTrials.gov registry search for "Selank," queried directly at clinicaltrials.gov/search?term=Selank.

Frequently asked questions

Q: Does Selank have any FDA-registered clinical trials?

A: No. As of this review, ClinicalTrials.gov lists no interventional or observational trials studying Selank. Its clinical evidence base comes from Russian Ministry of Health-registered research rather than the FDA/ClinicalTrials.gov system.

Q: Why isn't Selank listed on ClinicalTrials.gov if it has clinical trial data?

A: Selank's foundational trial was conducted and reviewed under Russia's national drug registration process, which maintains a separate trial registry from the U.S. system. Studies run exclusively within that framework do not automatically appear on ClinicalTrials.gov.

Q: What is the strongest published evidence for Selank's effects?

A: The most cited human data comes from a 2008 controlled trial in 62 patients with generalized anxiety disorder and neurasthenia, comparing intranasal Selank to the benzodiazepine medazepam over 14 days (PMID 18454096). Subsequent rodent studies have explored proposed GABAergic mechanisms.

Q: Is Selank's regulatory situation similar to Semax?

A: Yes. Semax shows the same pattern — a long history of Russian clinical registration and use, extensive preclinical publication, and no current ClinicalTrials.gov listing in the U.S. registry.

Q: How can researchers track if a U.S. trial for Selank is filed in the future?

A: The ClinicalTrials.gov registry updates continuously as new studies are submitted. Researchers can monitor new filings directly through the registry's search tool or through the site's trial tracker, which surfaces newly registered studies relevant to compounds covered here.

See also:

Selank and Semax: Complementary Anxiolytic and Nootropic Peptides — how the two peptides' mechanisms are studied together despite neither having a U.S. trial registry entry.
Best Peptides for Cognitive Research: 8 Compounds Studied for Brain Function — where Selank and Semax rank among other cognition-focused research compounds.
MOTS-C, DSIP, Epitalon & Semax: PCAC Docket Research Summary — Semax's current status in the FDA's July 2026 compounding review.

For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.